ABSTRACT
Cyclin E and its binding partner Cdk2 control the G1/S transition in mammalian cells. Increased levels of cyclin E are found in some cancers. Additionally, proteolytic removal of the cyclin E N-terminus occurs in some cancers and is associated with increased cyclin E–Cdk2 activity and poor clinical prognosis. Cyclin E levels are tightly regulated and controlled in part through ubiquitin-mediated degradation initiated by one of two E3 ligases, Cul1 and Cul3. Cul1 ubiquitylates phosphorylated cyclin E, but the mechanism through which Cul3 ubiquitylates cyclin E is poorly understood. In experiments to ascertain how Cul3 mediates cyclin E destruction, we identified a degron on cyclin E that Cul3 targets for ubiquitylation. Recognition of the degron and binding of Cul3 does not require a BTB domain-containing adaptor protein. Additionally, this degron is lacking in N-terminally truncated cyclin E. Our results describe a mechanism whereby N-terminally truncated cyclin E can avoid the Cul3-mediated degradation pathway. This mechanism helps to explain the increased activity that is associated with the truncated cyclin E variants that occurs in some cancers.
Footnotes
Author contributions
Conceptualization: B.D., K.R.d.O.R., J.D.S.; Methodology: B.D., K.R.d.O.R., J.D.S.; Formal analysis: B.D., K.R.d.O.R., J.D.S.; Investigation: J.D.S.; Resources: L.N.A., C.D.S.; Writing - original draft: B.D., K.R.d.O.R., J.D.S.; Writing - review & editing: B.D., K.R.d.O.R., J.D.S.; Supervision: J.D.S.; Project administration: J.D.S.; Funding acquisition: J.D.S.
Funding
This work was supported by the National Institutes of Health (R01 DK051496; sub award to J.D.S.). Deposited in PMC for release after 12 months.